Navigation Links
ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
Date:4/1/2008

IRVINE, Calif., April 1, 2008 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today reported topline results of a clinical trial of Xibrom(TM) (bromfenac sodium ophthalmic solution) QD (once-daily) 0.18% formulation, a new formulation of ISTA's ocular, non- steroidal anti-inflammatory agent. The findings demonstrated equivalence between the 0.18% formulation and ISTA's 0.09% formulation of Xibrom given once daily in achieving the primary efficacy endpoint of absence of ocular inflammation 15 days following surgery. The data also showed no statistically significant difference between the two formulations in achieving the secondary efficacy endpoints of elimination of ocular pain and mean reduction of markers of inflammation (inflammatory cells and flare). In addition, the results indicated both formulations of bromfenac produced a low overall incidence of ocular adverse events.

"We undertook this trial in connection with our Xibrom QD NDA application, which was submitted to the FDA in December 2007. The nearly identical performance of the two concentrations was unexpected and inconsistent with the previously available data. The results suggest the 0.09% formulation is near the top of the dose-response curve," stated Vicente Anido, Jr., Ph.D., President and Chief Executive Officer of ISTA Pharmaceuticals. "Our next steps are to complete the data analysis and speak with the FDA to determine a possible path forward, as well as consider other options in terms of new Xibrom products. Part of our discussions will be to review the possibility of a label change for the currently marketed 0.09% formulation of Xibrom so that it can be administered once-daily."

Conference Call

ISTA will host a conference call
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
2. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
3. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
4. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
5. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
6. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
7. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
8. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
9. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
10. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
11. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , March 3, 2015  3-D printing could ... treatments to individual patient needs, with clinicians having ... size and shape. That,s according to a study ... Radiology ,s Annual Scientific Meeting . Researchers ... filaments that were bioactive, giving these devices the ...
(Date:3/3/2015)... March 3, 2015  KaVo Kerr Group, a global ... new products at the 36 th International Dental ... Kerr Group delivers products and solutions to 99% of ... trade fair for the dental industry — the ideal ... to offer. The meeting, March 10-14, 2015, expects more ...
(Date:3/3/2015)... 2015  CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... commercial focus on China , announces ... Executive Officer, will be making a corporate presentation at ... 8-11 in Dana Point, CA.  Dr. Ren will present ...
Breaking Medicine Technology:3-D printing offers innovative method to deliver medication 23-D printing offers innovative method to deliver medication 33-D printing offers innovative method to deliver medication 4KaVo Kerr Group Prepares to Present 35+ New Products at the 36th IDS in Cologne 2KaVo Kerr Group Prepares to Present 35+ New Products at the 36th IDS in Cologne 3CASI Pharmaceuticals To Present At The 27th Annual ROTH Conference 2
... OXIS International, Inc., (OTC Bulletin Board: OXIS ... Executive Officer, and Bernie Landes, President, will present to ... Sciences & Medical Technologies On-Line Forum on Thursday, February ... A webcast of the presentation will be ...
... Hardy Diagnostics, an ISO certified biomedical firm, is pleased ... selective chromogenic medium recommended for use as a primary ... Salmonella and Shigella spp. from stool ... non-pathogenic enteric bacteria based on colony color. Differentiation of ...
Cached Medicine Technology:The Only Chromogenic Medium That Detects Both Salmonella and Shigella! 2
(Date:3/3/2015)... 2015 Raritan Bay Medical Center is ... an interactive photo contest held at the Woodbridge Center ... To raise awareness for health and wellness in the ... their best health and wellness tips. , Photos of ... Center’s website and Facebook page where Facebook users voted ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Claflin ... the Department of Veterans Affairs has signed a new, ... March 1, 2015. , Under the contract, the ... such as the U.S. Military, Indian Health Services, National ... local government entities with competitive pricing for hospital equipment ...
(Date:3/3/2015)... A newly launched program is available ... II diabetes, and pre-diabetes. As opposed to traditional pharmaceutical ... for diabetes sufferers to reverse their disease without the ... In 2013, the U.S. diabetes industry made $250 billion ... include the use of insulin and other glucose-controlling medications ...
(Date:3/3/2015)... T-System Inc. today announced ... CPHQ, FABC as the company’s chief nursing officer along ... episodic care. , “Today’s patients are demanding ... including urgent care and freestanding emergency centers one of ... Davis, T-System’s chief executive officer. “We have a ...
(Date:3/3/2015)... March 03, 2015 The Data 360 ... at the Ford Conference Center, Dearborn, MI, on March 5, ... Inc., is a featured speaker. He is known internationally as ... , These designations were earned due to years of ... commercially-available NoSQL DB, released over 10 years ago. Subsequent developments ...
Breaking Medicine News(10 mins):Health News:Raritan Bay Medical Center Announces Winners of “Picture of Health” Photo Contest 2Health News:Claflin Medical Equipment (CME) Announces New 5 Year Contract with the Department of Veterans Affairs (VA) 2Health News:New Breakthrough In Diabetes Reaserch Show Scientifically Proven Way To Reverse Your Diabetes Naturally In 30 Short Days 2Health News:T-System Renews Commitment to Clinically-Driven Innovation and Appoints Industry Leader as CNO 2Health News:T-System Renews Commitment to Clinically-Driven Innovation and Appoints Industry Leader as CNO 3Health News:Scientel® to Present at Data 360 Big Data Healthcare Conference, March 5, 2015, Dearborn, MI 2Health News:Scientel® to Present at Data 360 Big Data Healthcare Conference, March 5, 2015, Dearborn, MI 3Health News:Scientel® to Present at Data 360 Big Data Healthcare Conference, March 5, 2015, Dearborn, MI 4
... looking into Tamiflu; Relenza also under scrutiny. , , ... Food and Drug Administration panel is meeting Tuesday ... flu drug Tamiflu (oseltamivir), linked recently to anecdotal ... , The FDA,s Pediatric Advisory Committee will begin ...
... STORZ OR1(R) GIVES SURGEONS, GREATER ACCESS TO PATIENT DATA AND ... ... REMOTELY, ALISO VIEJO, Calif., Nov. 27 Global Care Quest, ... Inc., the world leader in minimally invasive,endoscopic technologies and operating room integration, ...
... Nov. 27 Merge Healthcare (Nasdaq:,MRGE; TSX: ... services provider,announced today that its Merge Healthcare ... Gold Seal of Approval(TM), by demonstrating,compliance with ... national standard for healthcare quality and safety. ...
... million Series A financing from Alta Partners, ... ProQuest Investments and RiverVest Venture Partners, CARLSBAD, ... Pharmaceuticals, Inc. (Nasdaq: ISIS ) and Excaliard ... and develop antisense,drugs for the local treatment of ...
... green product design granted the International HIDO ... Award, TORONTO, and GOLFE JUAN, France, Nov. ... specializing in sustainable and health,product innovations and HIDO, ... has received the HIDO,International Design Award. The Award ...
... MAR, Calif., Nov. 27 ,Awake, the movie is a,psychological ... awareness" and finds himself awake and aware, but paralyzed,during heart ... ,Coma, captured and terrified,the American public,s imagination. ,Coma, is the ... surgery -- and never wake up again., "Five years ...
Cached Medicine News:Health News:FDA Mulls Tougher Warning Label on Kids' Flu Drugs 2Health News:FDA Mulls Tougher Warning Label on Kids' Flu Drugs 3Health News:KARL STORZ and Global Care Quest Announce Extension of Marketing Agreement 2Health News:KARL STORZ and Global Care Quest Announce Extension of Marketing Agreement 3Health News:Merge Healthcare Teleradiology Division Receives Accreditation From Joint Commission 2Health News:Merge Healthcare Teleradiology Division Receives Accreditation From Joint Commission 3Health News:Isis and Excaliard Collaborate to Develop Antisense Drugs for Local Treatment of Fibrotic Diseases 2Health News:Isis and Excaliard Collaborate to Develop Antisense Drugs for Local Treatment of Fibrotic Diseases 3Health News:Isis and Excaliard Collaborate to Develop Antisense Drugs for Local Treatment of Fibrotic Diseases 4Health News:Isis and Excaliard Collaborate to Develop Antisense Drugs for Local Treatment of Fibrotic Diseases 5Health News:Cooler Solutions' 'Dignity Toilet' Wins International Design Competition by Providing Sanitation for Those in Need 2Health News:'Awake' the Movie Highlights the Need for 'Goldilocks' Anesthesia, Says Dr. Barry L. Friedberg, Developer of Bispectral Index (BIS) Monitored Propofol Ketamine Sedation, Now Trademarked as Minimally Invasive Anesthesia (MIA)(R) 2Health News:'Awake' the Movie Highlights the Need for 'Goldilocks' Anesthesia, Says Dr. Barry L. Friedberg, Developer of Bispectral Index (BIS) Monitored Propofol Ketamine Sedation, Now Trademarked as Minimally Invasive Anesthesia (MIA)(R) 3
... Oxygen Conservation Device. Bypass ... ,6200 Accessories: , OCD870C ... CGA 540 Regulator , OCD2001-18 ... Booklet , CP2140 Vertical M-6 ...
... with Accutrol is similar in design to ... it incorporates a temperature probe at the ... probe can accurately determine the patient's core ... temperature accuracy comparable to a pulmonary artery ...
... These markers are available with 16 or 24 circular ... diameter, and an outer 9.5mm diameter. The markers are ... one single step for a 16 or 24 running ... points on the cornea to achieve a precise and ...
... Shafts For Insertion Through A 1.0mm Incision., ... ... A More Comfortable Approach., ,Recessed Jaws For ... For Protection Of Jaws During Sterilization., ,Reusable, ...
Medicine Products: